Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Hold at StockNews.com

StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Thursday.

A number of other analysts have also commented on COLL. TheStreet lowered Collegium Pharmaceutical from a b- rating to a c+ rating in a research note on Monday, April 11th. Needham & Company LLC increased their price objective on Collegium Pharmaceutical from $34.00 to $36.00 and gave the company a buy rating in a research note on Wednesday, April 6th. Zacks Investment Research lowered Collegium Pharmaceutical from a hold rating to a strong sell rating in a research note on Tuesday, April 26th. Cantor Fitzgerald raised Collegium Pharmaceutical from a neutral rating to an overweight rating and increased their price objective for the company from $18.00 to $26.00 in a research note on Tuesday, February 15th. Finally, HC Wainwright raised their price target on Collegium Pharmaceutical from $26.00 to $29.00 and gave the stock a buy rating in a research note on Tuesday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of Buy and a consensus price target of $31.00.

Collegium Pharmaceutical stock opened at $16.36 on Thursday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.76 and a current ratio of 0.97. The firm has a market capitalization of $554.98 million, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 0.16 and a beta of 1.07. Collegium Pharmaceutical has a fifty-two week low of $14.04 and a fifty-two week high of $25.66. The stock’s fifty day moving average is $17.85 and its two-hundred day moving average is $18.49.

Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) last posted its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.46). The firm had revenue of $83.80 million during the quarter, compared to analyst estimates of $78.67 million. Collegium Pharmaceutical had a net margin of 15.68% and a return on equity of 3.26%. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period last year, the company posted $0.41 EPS. As a group, sell-side analysts forecast that Collegium Pharmaceutical will post 4.94 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Collegium Pharmaceutical by 126.3% in the 1st quarter. Royal Bank of Canada now owns 14,701 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 8,206 shares during the period. PDT Partners LLC purchased a new position in shares of Collegium Pharmaceutical in the 1st quarter worth about $301,000. Captrust Financial Advisors raised its holdings in shares of Collegium Pharmaceutical by 97.5% in the 1st quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock worth $44,000 after purchasing an additional 1,062 shares during the period. State Street Corp raised its holdings in shares of Collegium Pharmaceutical by 14.4% in the 1st quarter. State Street Corp now owns 1,308,167 shares of the specialty pharmaceutical company’s stock worth $26,634,000 after purchasing an additional 165,144 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Collegium Pharmaceutical by 1.1% in the 1st quarter. Invesco Ltd. now owns 1,010,612 shares of the specialty pharmaceutical company’s stock worth $20,576,000 after purchasing an additional 11,090 shares during the period.

Collegium Pharmaceutical Company Profile (Get Rating)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Further Reading